Summit Therapeutics (SMMT) is down -12.5%, or -$3.54 to $24.71.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SMMT:
- Summit Therapeutics price target raised to $33 from $30 at Clear Street
- Ivonescimab’s Promising Potential to Outperform KEYTRUDA: A Strong Buy Recommendation
- Summit Therapeutics Reports Q2 2025 Progress and Financials
- Closing Bell Movers: Green Dot up 20% after Q2 beat and raise
- Summit Therapeutics Amends Stock Distribution Agreement